Many patients with hematological neoplasms fail to mobilize sufficient numbers of hematopoietic stem cells (HSCs) in response to granulocyte colony-stimulating factor (G-CSF) precluding subsequent autologous HSC transplantation. Plerixafor, a specific antagonist of the chemokine receptor CXCR4, can rescue some but not all patients who failed to mobilize with G-CSF alone. These refractory poor mobilizers cannot currently benefit from autologous transplantation. To discover alternative targetable pathways to enhance HSC mobilization, we studied the role of hypoxia-inducible factor-1α (HIF-1α) and the effect of HIF-1α pharmacological stabilization on HSC mobilization in mice. We demonstrate in mice with HSC-specific conditional deletion of the Hif1a gene that the oxygen-labile transcription factor HIF-1α is essential for HSC mobilization in response to G-CSF and Plerixafor. Conversely, pharmacological stabilization of HIF-1α with the 4-prolyl hydroxylase inhibitor FG-4497 synergizes with G-CSF and Plerixafor increasing mobilization of reconstituting HSCs 20-fold compared with G-CSF plus Plerixafor, currently the most potent mobilizing combination used in the clinic.
INTRODUCTION
The cytokine granulocyte colony-stimulating factor (G-CSF) is the main agent to mobilize hematopoietic stem cells (HSCs) for transplantation. Administered daily at doses of 10 μg/kg, G-CSF mobilizes hematopoietic stem and progenitor cells (HSPCs) from the bone marrow (BM) into the circulation. In most healthy allogeneic donors, CD34 + HSPCs are robustly mobilized after 5 days of G-CSF treatment and blood aphaeresis from day 5 is sufficient to reach the minimum threshold of 2 × 10 6 CD34 + cells/kg body weight to ensure rapid hematopoietic reconstitution. However in the autologous setting, 20-60% of chemotherapytreated patients fail to reach this minimal threshold in response to G-CSF, precluding transplantation 1 particularly in patients with prior radiotherapy and chemotherapy. 1, 2 The chemotactic interaction between the chemokine CXCL12 and its receptor CXCR4 is pivotal to HSPC retention within the BM 3, 4 and is weakened by G-CSF treatment causing mobilization. [5] [6] [7] Additional inhibition of the CXCL12:CXCR4 interaction with specific small synthetic inhibitors such as Plerixafor (previously called AMD3100) synergistically enhances HSPC mobilization in response to G-CSF in humans and mice. 8 The synergistic effect of Plerixafor has been confirmed in large clinical trials with multiple myeloma and nonHodgkin lymphoma patients eligible for autologous HSC transplantation who previously failed to mobilize in response to G-CSF alone. Plerixafor injected daily 1 h before blood aphaeresis from day 4 of G-CSF administration enables approximately 70-80% patients who previously failed to mobilize in response to G-CSF alone to reach 2 × 10 6 CD34 + cells/kg threshold. 9, 10 However, the remaining 20-30% of patients who failed to mobilize with G-CSF alone still fail to mobilize with G-CSF and Plerixafor. 9, 10 It is therefore important to further understand the mechanisms of HSC mobilization to identify novel therapeutics to overcome mobilization failure in a larger proportion of patients.
The hypoxia sensing pathway is activated in the BM of mice mobilized with G-CSF. 11 Extensive myeloid progenitor proliferation in response to G-CSF is thought to enhance O 2 consumption increasing overall BM hypoxia, which in turn stabilizes the O 2 -labile protein hypoxia-inducible factor-1α (HIF-1α) in mobilized BM. 11 HIF-1α is a transcription factor that regulates metabolic adaptation and cell responses to hypoxia. [12] [13] [14] Considering the critical role of HIF-1α in regulating HSC proliferation, self-renewal and homing to the BM, [15] [16] [17] [18] we investigated its role in HSPC mobilization in mice.
MATERIALS AND METHODS Mice
C57BL/6 mice were purchased from the Australian Resource Centre, Perth, Australia; B6.129-Hif1a tm3Rsjo /J (Hif1a flox/flox ) mice from the Jackson Laboratory (Bar Harbor, ME, USA). Scl-CreER transgenic mice expressing a tamoxifen-inducible Cre recombinase driven by a HSC-specific Scl gene enhancer, 19 B6-Gt(ROSA)26 Sortm1(EYFP)Cos/J (abbreviated as R26R YFP ) with a loxP-flanked STOP sequence preceding an enhanced yellow fluorescent protein (YFP) reporter gene inserted into the genetrap ROSA26 locus 20 were backcrossed at least 10 times in C57BL/6 background. Mouse genotyping is described in Supplementary Methods.
Induction of the Scl-CreER transgene with tamoxifen
Scl-CreER mice were gavaged daily with tamoxifen-free base diluted in peanut oil containing 10% ethanol for 3 days to induce the Scl-CreER transgene. For mobilization experiments with G-CSF, G-CSF was administered for 3 days beginning on the final day of tamoxifen gavaging unless otherwise stated. For mobilization experiments with Plerixafor, Plerixafor was administered intraperitoneally 1 week following the final day of tamoxifen induction, 1 h before harvest. Following treatments, mice were then euthanized by cervical dislocation and BM and bones harvested. For migration assay and CXCR4 staining, mice were harvested 1 week following the final day of tamoxifen induction.
Mobilization
All experiments were performed on 9-to 12-week-old male mice. Recombinant human G-CSF was injected twice daily subcutaneously at 125 μg/kg and Plerixafor (AMD3100 octohydrochloride) intraperitoneally at 10 mg/kg as described. 21 Tissues were harvested 1 h after Plerixafor administration. FG-4497 was injected daily intraperitoneally at 20 mg/kg. Control mice were injected with an equivalent volume of saline. Tissues were harvested on the morning following the last G-CSF injection, or 1 h following Plerixafor injection.
For studies with additional 4-prolyl hydroxylase domain enzyme (PHD) inhibitors, G-CSF was administered twice daily subcutaneously for 4 consecutive days. PHI-1 and PHI-2 were administered daily by oral gavage at 20 mg/kg for the last 3 days of the mobilization regimen.
Tissue harvesting
Mice were anesthetized with isofluorane and approximately 1 ml of blood collected into heparinized tubes by cardiac puncture before cervical dislocation. Femoral BM was flushed and spleens dissociated between the frosted ends of two glass slides in phosphate-buffered saline containing 2% fetal calf serum (FCS) for further analyses. For flow-cytometry analyses, red cells were lysed from blood samples as previously described. 22 Spleens were harvested, weighed, dissociated in 10 ml phosphate-buffered saline with 2% FCS. RNA from the endosteum was isolated from femurs as previously described. 23 
Western blotting
Following treatment of mice with Saline, G-CSF or FG-4497, BM cells from one femur were flushed with 1 ml of urea cell lysis buffer containing complete protease inhibitors (Roche, Basel, Switzerland) supplemented with 200 μM phenylmethylsulfonyl fluoride. 16 Quantitative western blots with rabbit antimouse HIF-1α antibody were performed using the Odyssey Infra-Red Imaging System (Li-COR Bioscience, Lincoln, NE, USA) as described previously. 11, 16 Colony assays In all, 10 μl whole blood or splenocytes from 1/1000 of a whole spleen were seeded in 35-mm petri dishes and covered with 1 ml IMDM supplemented with 1.6% methylcellulose, 35% FCS and optimal concentrations of mouse IL-3, IL-6 and soluble kit ligand as described previously. 24 When results are reported as proportion of mobilized cells versus whole BM content, we considered that one femoral BM represents 5.6% of total mouse BM and that the total volume of blood is 0.08 ml per gram of body weight. 25, 26 Flow cytometry Antibody staining for expression of α4 and α5 integrins, PSGL1, CXCR4, binding of P-and E-selectins and for HSPC cell cycling are described in Supplementary Methods.
Quantitative real-time reversed transcribed PCR Quantitative real-time reversed transcribed PCR (qRT-PCR) to confirm Hif1a gene deletion in HSPC and measure Cxcr4, Cxcr7 and Cxcl12 mRNA is described in Supplementary Methods.
Competitive repopulation assays
The content of mobilized blood samples in competitive repopulating HSC was determined in competitive repopulation assays as previously described. 22, 24 
RESULTS
Hif1a gene deletion in HSPCs impairs their mobilization in response to G-CSF To test the hypothesis that HIF-1α has an important role in HSC mobilization, we established a mutant mouse strain in which both Hif1a gene alleles are specifically deleted and YFP reporter induced in a Cre-dependent manner 20 in HSCs following treatment with tamoxifen ( Figure 1a) . 19 Figure S1) . We also plated sorted Lin 
Hif1a
WT/WT mice 4 days after a 3-day induction with tamoxifen. Cxcr4 expression was however not altered by Hif1a deletion. We also tested for the expression of CXCR7, a related chemokine receptor previously shown to bind CXCL12 and dimerize and co-signal with CXCR4 on human CD34 + HSPCs. 28, 29 Using an anti-CXCR7 monoclonal antibody cross-reactive for human and mouse CXCR7, as well as TaqMan primer probe set for mouse Cxcr7 mRNA, we could not detect CXCR7 protein or mRNA in mouse BM HSPCs (data not shown), in agreement with expression array reported on www. biogps.org showing lack of expression in adult mouse HSCs.
FG-4497 synergizes with G-CSF to enhance mobilization As HIF-1α is critical to HSPC mobilization in response to G-CSF or Plerixafor (Figures 1 and 2) , we tested whether further stabilization of the HIF-1α protein, which is O 2 -labile, may enhance mobilization in response to G-CSF and Plerixafor. We injected wild-type mice with the PHD inhibitor FG-4497 to block HIF-1α proline hydroxylation in oxidative conditions and downstream recruitment of the ubiquitin ligase VHL and O 2 -dependant proteasomal degradation of HIF-1α. 16 ,30,31 HIF-1α protein was very low in BM cell lysates from saline-injected animals and significantly increased following G-CSF treatment (Figure 3a ) consistent with our previous findings.
11 However, treatment with FG-4497 or the combination of FG-4497 with G-CSF further increased HIF-1α protein levels compared with G-CSF alone (Figure 3a) .
We next treated C57BL/6 mice with G-CSF twice daily for 1-3 days together with the PHD inhibitor FG-4497 daily for the 3 days before tissue harvest. FG-4497 treatment on top of the 3 day G-CSF treatment increased CFCs mobilized per ml blood 2.5-fold following 2 days of G-CSF, and 6-fold the number of CFCs mobilized per spleen compared with G-CSF treatment alone (Figure 3b ). Of note, 3-day treatment with FG-4497 alone without G-CSF did not induce CFC mobilization into the blood compared with control mice injected with vehicle (not shown).
To evaluate the effect of FG-4497 treatment duration, FG-4497 was administered for 1-3 days and G-CSF for the last 2 days before tissue sampling (Figure 3c ). CFC mobilization into blood and spleen in response to 2 days of G-CSF progressively increased with the duration of FG-4497 treatment.
Of Figure S3) . Therefore, the enhancing effect of FG-4497 on HSPC mobilization is specifically mediated by HIF-1α protein.
FG-4497 synergizes with Plerixafor to enhance CFC mobilization Since mobilization with Plerixafor peaks 1 h post injection, 8 this time point was used together with daily administration of FG-4497 for 1-3 days before killing (Figure 3d ). CFCs mobilization into blood in response to Plerixafor was significantly increased by a 2-3 day treatment with FG-4497 treatment demonstrating synergy between CXCR4 inhibition and PHD inhibition. As mobilization in response to Plerixafor is very rapid, there was no significant mobilization of HSPCs to the spleen 1 h following Plerixafor treatment with or without FG-4497.
FG4497 does not increase mobilization by altering HSPC cycling or survival As we have previously reported that a 7-day FG-4497 treatment inhibits HSPC proliferation in vivo in mice in steady state, 16 we first evaluated 5-bromodeoxyuridine (BrdU) incorporation over 3 days and Ki67 antigen expression in BM HSPC from mice treated with Figure S4A) 
for G-CSF vs G-CSF plus FG4497
Role of HIF-1α in HSC mobilizationgroups). Therefore, this short FG-4497 treatment did not increase HSPC mobilization by altering their cycling. We also measured the effect of FG-4497 on HSPC apoptosis. In overnight cultures of BM cells with 10 ng/ml Kit ligand, addition of 40 μM FG-4997, a concentration that stabilizes HIF-1α in cultured HSPC, 32 did not alter the proportion of live non-apoptotic annexin V-negative, 7-aminoactinomycin D-negative HSPCs (Supplementary Figure  S4B) . Finally, FG-4497 treatment alone did not alter number of Lin − Kit + Sca1 + HSPC in the femoral BM compared with salinetreated mice. In contrast, the combination of 2 days G-CSF with 3 days FG-4497 reduced HSPC number in the BM significantly more than G-CSF alone treatment (Supplementary Figure S4C) . Therefore, increased mobilization with G-CSF plus FG-4497 is not due to an increase in HSPC number in the BM. Rather, the decrease in the number of HSPCs in the BM may reflect better mobilization efficiency. BM cells from these mice were also tested in a chemotaxis assay in the presence of 100 ng/ml CXCL12 in the bottom chamber. BM Lin − Kit + Sca1 + HSPC from mice treated with G-CSF plus FG-4497 migrated less toward CXCL12 compared with HSPC isolated from mice treated with G-CSF alone (Figure 4d ), suggesting that FG-4497 treatment decreases CXCR4 signaling in HSPC from mobilized mice.
When repeated in mice not treated with G-CSF, 3-day FG-4497 treatment did not increase CXCR4 expression on HSPC isolated from mice in steady state. Likewise, the FG-4497 treatment did not alter transmigration toward CXCL12 (not shown). This may explain why FG-4497 alone does not mobilize HSPC in vivo.
We extracted RNA from endosteal cells from the femurs of mice treated with saline, FG-4497 alone, G-CSF alone or combination of G-CSF plus FG-4497. qRT-PCR revealed that Cxcl12 mRNA was further decreased in the G-CSF plus FG-4497 combination group compared with G-CSF alone, suggesting that FG-4497 further reduce expression of CXCL12 by BM stromal cells in response to G-CSF (Figure 4e) . Interestingly, in the absence of G-CSF, treatment with FG-4497 alone did not alter Cxcl12 mRNA levels.
We also tested whether pharmacological stabilization of HIF-1α could alter adhesive interactions of HSPCs mediated by endothelial selectins, α4 and α5 integrins which are important to retain HSPC within the BM. [34] [35] [36] FG-4497 did not reduce binding of recombinant mouse E-selectin or P-selectin-IgG1 fusion proteins to BM HSPCs, although G-CSF treatment significantly reduced P-selectin binding (Supplementary Figure S5) . Cell surface expression of PSGL1, α4 and α5 integrins on BM HSPCs was not altered by in vivo treatments with FG-4497 (Supplementary Figure S5) .
Other PHD inhibitors enhance HSPC mobilization To further document the potentiating effect of PHD inhibitors on HSPC mobilization, C57BL/6 mice were treated with two additional novel PHD inhibitors (PHI-1 and PHI-2) from chemically distinct structural classes (US patents number 7 696 223 and 7 928 120). Although representing different chemical series, FG-4497, PHI-1 and PHI-2 are all structural mimetics of the PHD substrate 2-oxoglutarate and inhibitors of the HIF PHD enzymes. 37 Combinations of either PHI-1 or PHI-2 with G-CSF increased CFCs, Lin 
CD150
+ HSCs mobilization into blood compared with G-CSF alone treated animals ( Figure 5 ).
PHD inhibition synergizes with the combination of G-CSF and Plerixafor
Since FG-4497 synergized with either G-CSF or Plerixafor, we tested whether FG-4497 could further enhance the mobilizing effect of the combination of G-CSF with Plerixafor. Mice were treated with G-CSF for 2 or 4 days, with or without Plerixafor 1 h before harvest or with or without FG-4497 for 3 days prior harvest (Figure 6a) . The combination of G-CSF plus Plerixafor plus FG-4497 was much more potent at mobilizing CFCs, phenotypic HSPCs and HSCs to blood and spleen than the dual combination of G-CSF and Plerixafor (Figures 6b and d) . At day 4 of mobilization, the numbers of CFCs, phenotypic HSPCs and HSCs mobilized into blood were 2.4-fold, 5.7-fold and 5.7-fold higher with G-CSF, Plerixafor and FG-4497 than with G-CSF plus Plerixafor without FG-4497. Of note, the dual combination G-CSF plus FG-4497 mobilized CFCs, HSPCs and HSCs into blood better than the dual combination of G-CSF plus Plerixafor although mobilization to the spleen was equivalent with these two regimens. (Figures 7a and b) . Reconstitution with mobilized blood was significantly higher in all blood lineages (B, T and myeloid cells) (Figure 7c ) with G-CSF plus Plerixafor plus FG-4497, mobilizing repopulating units 1.8-fold more at day 2, and 20-fold more at day 4 than the dual combination G-CSF plus Plerixafor (Figures 7a and b) .
Long-term competitive transplantation assays also confirmed that G-CSF plus FG-4497 mobilized repopulating units 16-fold more than the combination of G-CSF plus Plerixafor at day 4 with higher multi-lineage chimerism.
DISCUSSION
Using conditional deletion of the Hif1a gene specifically in HSCs and immature HSPCs, we demonstrate that HIF-1α is required for HSPC mobilization in response to G-CSF or Plerixafor. More relevant to the clinic, we also demonstrate that pharmacological stabilization of HIF-1α protein with small synthetic PHD inhibitors synergizes with both G-CSF and Plerixafor to increase HSC mobilization into the blood. Indeed, additional stabilization of HIF-1α protein with the PHD inhibitor FG-4497 increased 20-fold the long-term repopulation potential of blood mobilized with G-CSF plus Plerixafor, currently the best available therapeutic combination to mobilize HSCs in autologous patients that previously failed to mobilize with G-CSF alone. This was not due to an off-target effect of FG-4497 as this drug did not enhance mobilization of HSPCs conditionally deleted for the Hif1a gene. Furthermore, other PHD inhibitors from different structural classes also enhanced HSPC mobilization similar to FG-4497. The synergistic effect of PHD inhibitors on HSC mobilization and engraftment upon transplantation is consistent with the recent finding that a short exposure ex vivo of HSPCs to dimethyl prostaglandin E2 stabilizes HIF-1α and subsequently doubles HSC homing to the BM and long-term engraftment. 18 Therefore, in vivo treatment with PHD inhibitors may have the double advantage of (1) quantitatively increasing the number of HSCs mobilized into the blood and (2) increasing their subsequent homing and engraftment efficiency once transplanted.
Mechanistically, we show that Hif1a gene deletion inhibited HSPC mobilization in response to the CXCR4 inhibitor Plerixafor, and reduced their migration toward CXCL12 gradient without altering Cxcr4 mRNA expression. However, due to the extremely low levels of CXCR4 protein at the surface of mouse HSPCs in the BM, we could not detect significant changes in CXCR4 protein at the surface of HSPCs following Hif1a gene deletion. Because of this we could not detect changes in cell surface CXCR4 protein on HPSCs from mice treated with FG-4497. However, treatment of wild-type mice with FG-4497 alone or in combination with G-CSF, which further stabilizes HIF-1α protein, significantly reduced intracellular CXCR4 protein in HSPCs compared with mice treated with saline or with G-CSF alone. However, FG-4497 treatment did not alter Cxcr4 mRNA expression in HSPCs. This is consistent with previous findings showing that deletion of Hif1a gene in all hematopoietic cells and in stromal cells in Mx1-Cre Hif1a fl/fl mice did not alter Cxcr4 mRNA or CXCR4 protein surface expression on HSPCs. 17 In addition, we found that in vitro chemotaxis of BM HSPCs isolated from mice treated with G-CSF plus FG-4497 was also decreased compared with HSPCs from mice treated with G-CSF alone. This is in contrast with a recent report that ex vivo treatment of BM HSPCs with dimethyl prostaglandin E2, which also increases HIF-1α protein, enhanced HSPC transmigration toward CXCL12. 18 A possible reason for this discrepancy is that dimethyl prostaglandin E2 was used in ex vivo once HSCs removed from their physiological niches while in our experiments, FG-4497 was administered in vivo. Also, dimethyl prostaglandin E2 is likely to activate via its four receptors EP1-4 many other pathways in addition to HIF-1α. 38 Finally, we found that the combination of FG-4497 plus G-CSF further exacerbated the reduction of Cxcl12 mRNA expression in the BM stroma in response to G-CSF. Therefore, the effect of FG-4497 is likely mediated in part by perturbation of CXCR4 signaling (HSPC autonomous effect) and CXCL12 expression (extrinsic effect) in G-CSF-treated mice, which may ultimately lead to enhanced mobilization. In summary, our data suggest that in G-CSF-treated mice, HIF-1α stabilization with FG-4497 qualitatively alters or quantitatively decreases CXCR4 chemotactic signaling. However, as HIF-1α activates the transcription of hundreds of genes, 14, 39 it is likely that HIF-1α enhances HSPC mobilization via several parallel mechanisms. Therefore, the effect of HIF-1α stabilization on HSPC mobilization is likely to be complex resulting from both HSC autonomous mechanisms and stroma mediated-mechanisms. Ongoing studies in our laboratory to profile the transcriptome of HSPCs from mice treated with FG-4497 will provide insights about its additional mechanisms of action on HSPC mobilization. If corroborated in humans, then our current study suggests that PHD inhibitors such as FG-4497 could advantageously replace Plerixafor or be added to G-CSF and Plerixafor to form an even more potent mobilizing cocktail that could further reduce the numbers of patients who fail to mobilize sufficiently to proceed with autologous HSC transplantation. Indeed, PHD inhibitors are safe in humans and currently tested in several clinical trials to treat anemia associated with chronic renal diseases. 37 Therefore, PHD inhibitors may have the potential to (1) reduce the high cost of remobilization 40, 41 and make it more accessible to patients requiring autologous HSC transplant and (2) be used upfront with G-CSF to increase the number of HSCs harvested in both the allogeneic and autologous setting as transplantation of higher doses of HSCs (45 × 10 6 CD34 + cells/kg) further reduce the period of cytopenia, risks of potentially fatal febrile neutropenia, and transfusion costs associated with prolonged anemia and thrombocytopenia.
In conclusion, our work demonstrates that HIF-1α is necessary to HSPC mobilization in mice and opens the perspective of using PHD inhibitors in combination with G-CSF to boost HSC mobilization for transplantation in humans.
